viewSareum Holdings PLC

Licensing deal ‘a validation of Sareum’s business model’

The chief executive of drug discovery and development firm Sareum Holdings Plc (LON:SAR), Dr Tim Mitchell, tells Proactive that the recent licensing deal the company signed with ProNAi proves that its business model works.

“We validated our business model, in that we’ve taken our products into clinical trials and executed licensing deals and that’s what we’ve done,” Mitchell says.

The agreement will see Sareum receive US$1.9mln upfront, future milestone payments of up to US$88.4mln, as well as some royalties from any product that is successfully developed as a result.

Mitchell adds: “Of course, the cash that comes in from the deal is very handy too.”

He says that now that deal is completed, the company can kick on with the development of its other products.

“We can really focus our spending now on TK2, both on the autoimmune disease side and the cancer side, and then look for other assets to replace Chk1.”

Quick facts: Sareum Holdings PLC

Price: 0.365 GBX

Market: AIM
Market Cap: £11.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...



Sareum Holdings new licensing deal 'could generate significant near-term...

Sareum Holdings PLC's (LON:SAR) Tim Mitchell speaks to Proactive's Andrew Scott soon after announcing a licensing deal with an unnamed Chinese specialty pharmaceutical company. The firm will develop Sareum's FLT3+Aurora kinases portfolio, including SAR-20293, a preclinical drug candidate for...

1 day, 13 hours ago

2 min read